CVM
Price
$1.60
Change
-$0.01 (-0.62%)
Updated
Oct 22, 04:58 PM (EDT)
Capitalization
28.49M
62 days until earnings call
Intraday BUY SELL Signals
NRXS
Price
$7.72
Change
-$0.20 (-2.53%)
Updated
Oct 22, 04:59 PM (EDT)
Capitalization
99.46M
18 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CVM vs NRXS

CVM vs NRXS Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
CVM vs. NRXS commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CVM is a Hold and NRXS is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for CVM with price predictions
Oct 22, 2026

CVM's RSI Oscillator leaves overbought zone

The 10-day RSI Oscillator for CVM moved out of overbought territory on October 07, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 20 instances where the indicator moved out of the overbought zone. In 19 of the 20 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CVM as a result. In 90 of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

The Moving Average Convergence Divergence Histogram (MACD) for CVM turned negative on October 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 41 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

CVM moved below its 50-day moving average on October 19, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CVM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

CVM broke above its upper Bollinger Band on September 30, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +4.68% 3-day Advance, the price is estimated to grow further. Considering data from situations where CVM advanced for three days, in 175 of 221 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.

The Aroon Indicator entered an Uptrend today. In 52 of 60 cases where CVM Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 87%.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. CVM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 74 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 98 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.601) is normal, around the industry mean (2.973). P/E Ratio (-0.959) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.370) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CVM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for NRXS with price predictions
Oct 22, 2026

NRXS's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for NRXS turned positive on October 16, 2026. Looking at past instances where NRXS's MACD turned positive, the stock continued to rise in 27 of 30 cases over the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 15, 2026. You may want to consider a long position or call options on NRXS as a result. In 58 of 67 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 87%.

NRXS moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for NRXS crossed bullishly above the 50-day moving average on September 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.

Following a +19.08% 3-day Advance, the price is estimated to grow further. Considering data from situations where NRXS advanced for three days, in 122 of 146 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

NRXS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The 10-day RSI Indicator for NRXS moved out of overbought territory on September 25, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 14 similar instances where the indicator moved out of overbought territory. In 10 of the 14 cases, the stock moved lower in the following days. This puts the odds of a move lower at 71%.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NRXS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. NRXS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 59 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 73 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (14.775) is normal, around the industry mean (2.973). P/E Ratio (-10.421) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (14.225) is also within normal values, averaging (438.009).

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NRXS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
CVM: Fundamental Ratings
CVM
OUTLOOK RATING
1..100
88
VALUATION
overvalued / fair valued / undervalued
1..100
98
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
63
P/E GROWTH RATING
1..100
74
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
CVMNRXS
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
71%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
79%
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
87%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
89%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
83%
Advances
ODDS (%)
Bullish Trend 7 days ago
79%
Bullish Trend 8 days ago
84%
Declines
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 10 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
87%
N/A
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (CVM: $1.61 vs. NRXS: $7.92)
Brand notoriety: CVM: Notable vs. NRXS: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CVM: 39% vs. NRXS: 48%
Market capitalization -- CVM: $28.49M vs. NRXS: $99.46M
CVM [@Biotechnology] is valued at $28.49M. NRXS’s [@Biotechnology] market capitalization is $99.46M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $135.64B. The average market capitalization across the [@Biotechnology] industry is $2.14B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CVM’s FA Score shows that 0 FA rating(s) are green while NRXS’s FA Score has 0 green FA rating(s).

  • CVM’s FA Score: 0 green, 5 red.
  • NRXS’s FA Score: 0 green, 5 red.
According to our system of comparison, NRXS is a better buy in the long-term than CVM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CVM’s TA Score shows that 3 TA indicator(s) are bullish while NRXS’s TA Score has 6 bullish TA indicator(s).

  • CVM’s TA Score: 3 bullish, 6 bearish.
  • NRXS’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, NRXS is a better buy in the short-term than CVM.

Price Growth

CVM (@Biotechnology) experienced а -7.47% price change this week, while NRXS (@Biotechnology) price change was +21.29% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.17%. For the same industry, the average monthly price growth was -18.21%, and the average quarterly price growth was -15.24%.

Reported Earning Dates

CVM is expected to report earnings on Dec 23, 2026.

NRXS is expected to report earnings on Nov 09, 2026.

Industries' Descriptions

@Biotechnology (-1.17% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
CVM
Daily Signal:
Gain/Loss:
NRXS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

NRXS and

Correlation & Price change

A.I.dvisor indicates that over the last year, NRXS has been loosely correlated with CVM. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if NRXS jumps, then CVM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NRXS
1D Price
Change %
NRXS100%
-4.04%
CVM - NRXS
58%
Loosely correlated
-0.62%
ANRO - NRXS
28%
Poorly correlated
-4.80%
NTLA - NRXS
27%
Poorly correlated
-4.21%
RXRX - NRXS
26%
Poorly correlated
-1.65%
PMVP - NRXS
26%
Poorly correlated
-4.04%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SIGI91.740.66
+0.72%
Selective Insurance Group
RSKD8.92-0.03
-0.34%
Riskified Ltd
RCL286.13-2.32
-0.80%
Royal Caribbean Group
AVNW18.73-0.84
-4.29%
Aviat Networks
VTIX0.71-0.07
-8.89%
Virtuix Holdings Inc